Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma
Head & Neck · 2023-07 · 45 (7) · 1801-1811
DOI: 10.1002/hed.27395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, online erschienen am 15.05.2023. Verfasst von Jun Aoyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Function in Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Carcinoma, Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
We previously established a patient‐derived xenograft (PDX) model, patient‐derived organoids (PDOs), and PDX‐derived organoids (PDXOs) for salivary duct carcinoma (SDC). Using these models, this study examined the therapeutic effect of human epidermal growth factor receptor 2 (HER2) blockade on HER2‐positive SDC.
Methods
The therapeutic effect of lapatinib was assessed in SDC PDXOs with regards to cell growth, receptor/downstream signaling molecule expression, phosphorylation levels, and apoptosis. Effect of lapatinib treatment was evaluated in vivo in SDC PDX mice.
Results
The siRNA knockdown of HER2 and lapatinib suppressed cell proliferation in SDC PDXOs. Lapatinib inhibited the phosphorylation of HER2 and its downstream targets, and induced apoptosis in SDC PDXOs. Lapatinib also significantly reduced tumor volumes compared with that of the control in SDC PDX mice.
Conclusion
For the first time, we demonstrated the efficacy of anti‐HER2 therapy in HER2‐positive SDC using preclinical models of SDC PDX and PDXO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Function in Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Otorhinolaryngology-Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.
ORCID-Profile: Daisuke Sano, Hideaki Takahashi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Aoyama, J., Nojima, Y., Sano, D., Hirai, Y., Kijima, N., Aizawa, Y., Takada, K., Hatano, T., Takahashi, H., Nishimura, G., & Oridate, N. (2023). Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma. Head & Neck, 45(7), 1801-1811. https://doi.org/10.1002/hed.27395
Vancouver
Aoyama J, Nojima Y, Sano D, Hirai Y, Kijima N, Aizawa Y, et al. Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma. Head & Neck. 2023;45(7):1801-1811. doi:10.1002/hed.27395
BibTeX
@article{Aoyama2023,
author = {Aoyama, Jun and Nojima, Yusuke and Sano, Daisuke and Hirai, Yuri and Kijima, Natsumi and Aizawa, Yoshihiro and Takada, Kentaro and Hatano, Takashi and Takahashi, Hideaki and Nishimura, Goshi and Oridate, Nobuhiko},
title = {Effect of HER2 ‐targeted therapy on PDX and PDX ‐derived organoids generated from HER2 ‐positive salivary duct carcinoma},
journal = {Head & Neck},
year = {2023},
volume = {45},
number = {7},
pages = {1801--1811},
doi = {10.1002/hed.27395}
}
EUVIMED